We evaluated the effectiveness of doxazosin on ED in patients with LUTS/BPH and ED by using symptom score scales. We also evaluated whether or not the presence of asymptomatic inflammatory prostatitis had an effect on the alteration in the symptom scores.
Patients and Methods
A total of 36 male patients were included in the study. For all the cases, “International Prostate Symptom Score” (IPSS), “National Health Institute Chronic Prostatitis Symptom Index” (NIH-CPSI) and “International Index of Erectile Function” (IIEF-5) were investigated, and the scores were calculated in the first visit. Doxazosin was given for 30 days, and at the second visit IPSS, NIH-CPSI and IIEF-5 scores, Qmax and PMR were once more analysed. Afterwards, the alterations of the scores between visits were statistically compared.
Mean age of the 36 cases included in the study was 59.03 ± 1.35. The alterations in parameters between 1st and 2nd visit were compared in the cases who used doxazosin and a statistically significant decrease in IPSS, NIH-CPSI scores and statistically significant increase in Qmax were observed. Besides, there was a statistically significant increase in IIEF-5 score. In addition, when the cases were divided into two groups patients with asymptomatic inflammatory prostatitis and without asymptomatic inflammatory prostatitis, there was not any difference in all scores.
Doxazocin use in cases with LUTS/BPH and ED has an improving effect on ED as well as LUTS. Therefore, we believe that in the future, single agents or combined therapies might have a place in cases with LUTS/BPH and ED.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
McVary KT (2005) Erectile dysfunction and lower urinary tract symptoms secondary to BPH. Eur Urol 47:838–845
Costabile RA, Steers WD (2006) How can we best characterize the relationship between erectile dysfunction and benign prostatic hyperplasia? J Sex Med 3:676–681
Carson CC (2006) Combination of phosphodiesterase-5 inhibitors and alpha-blockers in patients with benign prostatic hyperplasia: treatments of lower urinary tract symptoms, erectile dysfunction, or both? BJU Int 97:39–43
Shiri R, Häkkinen JT, Hakama M et al (2005) Effect of lower urinary tract symptoms on the incidence of erectile dysfunction. J Urol 174:205–209
Lowe FC (2005) Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function. BJU Int 95:12–18
Krieger JN, Nyberg L Jr, Nickel JC (1999) NIH consensus definition and classification of prostatitis. JAMA 282:236–237
Barry MJ, Fowler FJ Jr, O’Leary MP et al (1992) The American Urological Association Symptom Index for benign prostatic hyperplasia. J Urol 148:1549–1557
Rosen RC, Cappelleri JC, Smith MD et al (1999) Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11:319–326
Marszalek M, Wehrberger C, Hochreiter W et al (2007) Symptoms suggestive of chronic pelvic pain syndrome in an urban population: prevalence and associations with lower urinary tract symptoms and erectile function. J Urol 177:1815–1819
Rosen RC, Giuliano F, Carson CC (2005) Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 47:824–837
McVary K (2006) Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 97:23–28
Braun MH, Sommer F, Haupt G et al (2003) Lower urinary tract symptoms and erectile dysfunction: co-morbidity or typical “Aging Male” symptoms? Results of the “Cologne Male Survey”. Eur Urol 44:588–594
Rosen R, Altwein J, Boyle P et al (2003) Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44:637–649
Rosen RC, Wei JT, Althof SE et al (2009) Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: results from the BPH registry. Urology 73:562–566
Kirby RS, Andersen M, Gratzke P et al (2001) A combined analysis of double-blind trials of the efficacy and tolerability of doxazosin-gastrointestinal therapeutic system, doxazosin standard and placebo in patients with benign prostatic hyperplasia. BJU Int 87:192–200
De Rose AF, Carmignani G, Corbu C et al (2002) Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. Urol Int 68:95–98
Fawzy A, Braun K, Lewis GP et al (1995) Doxazosin in the treatment of benign prostatic hyperplasia in normotensive patients: a multicenter study. J Urol 154:105–109
Andersen M, Dahlstrand C, Høye K (2000) Double-blind trial of the efficacy and tolerability of doxazosin in the gastrointestinal therapeutic system, doxazosin standard, and placebo in patients with benign prostatic hyperplasia. Eur Urol 38:400–409
Kirby RS, Roehrborn C, Boyle P et al (2003) Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the prospective European doxazosin and combination therapy (PREDICT) trial. Urology 61:119–126
Robert G, Descazeaud A, Nicolaïew N et al (2009) Inflammation in benign prostatic hyperplasia: a 282 patients’ immunohistochemical analysis. Prostate 69:1774–1780
About this article
Cite this article
Faydaci, G., Kuyumcuoglu, U., Eryildirim, B. et al. Effectiveness of doxazosin on erectile dysfunction in patients with lower urinary tract symptoms. Int Urol Nephrol 43, 619–624 (2011). https://doi.org/10.1007/s11255-010-9847-z
- Asymptomatic inflammatory prostatitis
- Erectile dysfunction
- Lower urinary tract symptoms